c-MET anticorps (pTyr1349, pTyr1356)

N° du produit ABIN401382

Détail du produit anti-c-MET anticorps

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Épitope: pTyr1349, pTyr1356

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp c-MET est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificité: This antibody is specific for c-Met protein phosphorylated at Y1349 and Y1356.

Réactivité croisée (Details): Species reactivity (expected):Mouse, Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography

Immunogène: Synthetic peptide corresponding to residues surrounding Y1349 and Y1356 of human c-Met protein

Isotype: IgG

Information d'application

Indications d'application: ELISA: 1/450,000. Western Blot: 1/500 - 1/2,000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.47 mg/mL (by UV absorbance at 280 nm)

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2 containing 0.01 % (w/v) Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Détails sur c-MET

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: HGF Receptor (MET Produits)

Synonymes: anticorps AUTS9, anticorps HGFR, anticorps RCCP2, anticorps c-Met, anticorps AI838057, anticorps HGF, anticorps Par4, anticorps Hgfr, anticorps c-met, anticorps MET, anticorps C-MET, anticorps met, anticorps met-A, anticorps MET proto-oncogene, receptor tyrosine kinase, anticorps met proto-oncogene, anticorps MET proto-oncogene, receptor tyrosine kinase L homeolog, anticorps MET, anticorps Met, anticorps met.L

Sujet: C-Met is the receptor for hepatocyte growth factor (also known as scatter factor, HGF/SF), and belongs to the tyrosine kinase superfamily. Interaction of c-Met with HGF results in autophosphorylation of c-Met at multiple tyrosines. Phosphorylation of Y1234/1235 in the c-Met kinase domain is critical to kinase activation. When phosphorylated, Y1349 and Y1356, along with surrounding amino acids, form a unique bidentate docking site for substrates such as Gab1, Grb2, phosphatidylinositol 3-kinase (PI3K) and others. C-Met mainly uses the Gab1 scaffolding adaptor in its initial step of signal transmission. Well-characterized downstream signalling pathways that are activated by c-Met include the ERK/MAPK, PI3K-Akt/PKB, Crk-Rap and Rac-Pak pathways, resulting in proliferation and increased cell survival as well as complex motogenic and morphogenic cellular responses. Gene targeting in mice has allowed elucidation of some of the developmental roles of c-Met and HGF/SF, such as their essential function in the formation of skeletal muscle, placenta and liver. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid and kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met

ID gène: 4233

NCBI Accession: NP_000236

UniProt: P08581

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor